Literature DB >> 14764079

Genetic deficiency of CD16, the low-affinity receptor for immunoglobulin G, has no impact on the functional capacity of polymorphonuclear neutrophils.

C Wagner1, G M Hänsch.   

Abstract

BACKGROUND: Of the three receptors for immunoglobulin G (IgG), the low-affinity receptor CD16 is constitutively expressed on polymorphonuclear neutrophils (PMNs), monocytes and NK-cells. CD16 participates in various effector functions, notably phagocytosis of opsonized particles or of immune complexes, and in antibody-dependent cellular cytotoxicity (ADCC). In the present study we report a case of total CD16 deficiency on PMNs and monocytes.
DESIGN: Polymorphonuclear neutrophils, monocytes and NK-cells were analyzed for surface-receptor expression by cytofluorometry and laser scan microscopy. Moreover, CD16-specific mRNA was assessed by RT-PCR. As functional parameters, phagocytosis of opsonized bacteria was tested, as was superoxide production.
RESULTS: Polymorphonuclear neutrophils and monocytes totally deficient in CD16 were detected by chance in an apparently healthy individual. Further analysis revealed that two more members of his family, his father and sister, were also deficient in CD16. All were healthy and there was no evidence of an increased frequency, or of exceptionally severe or persistent infections. Despite the lack of CD16, phagocytosis of antibody-coated bacteria was within the normal range, as was the superoxide production.
CONCLUSION: Deficiency of CD16 does not compromise the host defence. Apparently, the other receptors for IgG, CD32 and CD64, can compensate for the lack of CD16.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764079     DOI: 10.1111/j.1365-2362.2004.01298.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections.

Authors:  M M Gaida; F Günther; C Wagner; H Friess; N A Giese; J Schmidt; G M Hänsch; M N Wente
Journal:  Clin Exp Immunol       Date:  2008-09-05       Impact factor: 4.330

2.  Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation.

Authors:  Josée Golay; Rut Valgardsdottir; Gerta Musaraj; Damiano Giupponi; Orietta Spinelli; Martino Introna
Journal:  Blood       Date:  2019-01-17       Impact factor: 22.113

3.  FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.

Authors:  Louise W Treffers; Michel van Houdt; Christine W Bruggeman; Marieke H Heineke; Xi Wen Zhao; Joris van der Heijden; Sietse Q Nagelkerke; Paul J J H Verkuijlen; Judy Geissler; Suzanne Lissenberg-Thunnissen; Thomas Valerius; Matthias Peipp; Katka Franke; Robin van Bruggen; Taco W Kuijpers; Marjolein van Egmond; Gestur Vidarsson; Hanke L Matlung; Timo K van den Berg
Journal:  Front Immunol       Date:  2019-01-30       Impact factor: 7.561

4.  Investigation of the response of tear-film neutrophils to interleukin 8 and their sensitivity to centrifugation, fixation, and incubation.

Authors:  Yutong Jin; Lyndon Jones; Maud Gorbet
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

Review 5.  Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry.

Authors:  Margarida Lima
Journal:  Pract Lab Med       Date:  2020-03-10

6.  Inflammatory responses to acute exercise during pulmonary rehabilitation in patients with COPD.

Authors:  Alex R Jenkins; Neil S Holden; Arwel W Jones
Journal:  Eur J Appl Physiol       Date:  2020-08-07       Impact factor: 3.078

7.  Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake.

Authors:  Lisa C Willcocks; Paul A Lyons; Menna R Clatworthy; James I Robinson; Wanling Yang; Stephen A Newland; Vincent Plagnol; Naomi N McGovern; Alison M Condliffe; Edwin R Chilvers; Dwomoa Adu; Elaine C Jolly; Richard Watts; Yu Lung Lau; Ann W Morgan; Gerard Nash; Kenneth G C Smith
Journal:  J Exp Med       Date:  2008-06-16       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.